Treatment of viral hepatitis B in children

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 6, 2010, Pages 889-903

  Giacchino, Raffaella ^a   Cappelli, Barbara ^a  

^a G GASLINI INSTITUTE   (Italy)

Author keywords

CHB; Children; HBV; Treatment

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ALPHA TOCOPHEROL; ENTECAVIR; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; LEVAMISOLE; PEGINTERFERON ALPHA; PLACEBO; PREDNISOLONE; TELBIVUDINE; TENOFOVIR DISOPROXIL; VIRUS DNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANOREXIA; ANTIVIRAL ACTIVITY; BONE MARROW SUPPRESSION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DEPRESSION; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FEVER; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEBRILE CONVULSION; FLU LIKE SYNDROME; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GENOTYPE; HEPATITIS B; HUMAN; HYPOTHYROIDISM; IMMUNOCOMPROMISED PATIENT; IMMUNOMODULATION; INJECTION SITE PAIN; INJECTION SITE SWELLING; IRRITABILITY; LIVER INJURY; MONOTHERAPY; RETREATMENT; REVIEW; SEROCONVERSION; SIDE EFFECT; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRUS REPLICATION;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HEPATITIS B, CHRONIC; HUMANS; IMMUNOLOGIC FACTORS; LIVER; PATIENT SELECTION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77949891974     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656561003642006     Document Type: Review

References (117)

1. World Health Organization. Department of Immunization Vaccines and Biologicals.WHO vaccine-preventable disease: monitoring system 2006 Global summary. Available from www.who.int/vaccines-documents [Last accessed 1 Dec 2009] Overview of the different aspects of HBV infection
2. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004;11:97-107
3. Chen CJ, Wang LY, Yu MW. Epidemiology of hepatitis B virus infection in the Asia-Pacific region. J Gastroenterol Hepatol 2000;15:E3-6
4. Gust ID. Epidemiology of hepatitis B infection in the Western Pacific and South East Asia. Gut 1996;38:S18-23
5. Hepatitis B. World Health Organization Fact Sheet 204. World Health Organization, 2008. Avaiable from: http://www.who.int/mediacentre/ factsheets/en/[Last accessed 1 Dec 2009]
6. Lok AS. Chronic hepatitis B. N Engl J Med 2002;346:1682-1683
7. Chang M-H. Natural history of hepatitis B virus infection in children. J Gastroenterol Hepatol 2000;15:E16-19
8. Giacchino R, Zancan L, Vajro P, et al. Hepatitis B virus infection in native versus immigrant or adopted children in Italy following the compulsory vaccination. Infection 2001;29:188-191
9. Lin K, Vickery J. Screening for hepatitis B virus infection in pregnant women: evidence for the US Preventive Services Task Force reaffirmation recommendation statement. Ann Intern Med 2009;150:874-876
10. Van Herck K, Van Damme P. Benefits of early hepatitis B immunization programs for newborns and infants. Pediatr Infect Dis 2008;27:861-869
11. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000 summary of a workshop. Gastroenterology 2001;120:1828-1853
12. Lalazar G, Rund D, Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol 2007;136:699-712
13. Gigliotti AR, Fioredda F, Giacchino R. Hepatitis B and C infection in children undergoing chemotherapy or bone marrow transplantation. J Pediatr Hematol Oncol 2003;25:184-192
14. Yuen M-F, Lai C-L. Natural history of chronic hepatitis B virus infection. J Gastroenterol Hepatol 2000;15:E20-4
15. Bortolotti F. Chronic viral hepatitis in childhood. Baillieres Clin Gastroenterol 1996;10:185-206
16. Boxall EH, Sira J, Standish RA, et al. Natural history of hepatitis B in perinatally infected carriers. Arch Dis Child Fetal Neonatal Ed 2004;89:F456-60
17. Bortolotti F, Jara P, Crivellaro C, et al. Outcome of chronic hepatitis B in Caucasian children during a 20-year observation period. J Hepatol 1998;29:184-190
18. Bortolotti F, Wirth S, Crivellaro C, et al. Long-term persistence of hepatitis B virus DNA in the serum of children with chronic hepatitis B after hepatitis B e antigen to antibody seroconversion. J Ped Gastroenterol Nutr 1996;22:270-274
19. Bortolotti F, Guido M, Bartolacci S, et al. Chronic hepatitis B in children after e antigen seroclearance: final report of a 29-year longitudinal study. Hepatology 2006;43:556-562
20. Marx G, Martin SR, Chicoine JF, Alvarez F. Long-term follow-up of chronic hepatitis B virus infection in children of different ethnic origins. J Infect Dis 2002;186:295-301
21. Chu CJ, Hussain M, Lok AS. Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection. Hepatology 2002;36:1408-1415
22. Zacharakis G, Koskinas J, Kotsiou S, et al. Natural history of chronic hepatitis B virus infection in children of different ethnic origins: a cohort study with up to 12 years' follow-up in northern Greece. J Pediatr Gastroenterol Nutr 2007;44:84-91
23. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45:507-539
24. Beasley RP, Hwang LY. Overview on the epidemiology of hepatocellular carcinoma. In: Hollinger FB, Lemon SM, Margolis H, editors, Viral hepatitis and liver disease. William & Wilkins, Baltimore, MD; 1991. p. 532-535
25. Sumi H, Youkosuka O, Seki N, et al. Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease. Hepatology 2003;37:19-26
26. Hsu HY, Tsai HY, Wu TC, et al. Interferon-alpha treatment in children and young adults with chronic hepatitis B: a long-term follow-up study in Taiwan. Liver Int 2008;28:1288-1297
27. Chang MH, Hsu HY, Ni YH, et al. Precore stop codon mutant in chronic hepatitis B virus infection in children: its relation to hepatitis B e seroconversion and maternal hepatitis B surface antigen. J Hepatol 1998;28:915-922
28. Godra A, Perez-Atayde AR, Jonas MM. Histopathologic features of chronic hepatitis B in children. Hepatology 2005;42:478-9A
29. Giacchino R, Navone C, Facco F, et al. HBV-DNA-related hepatocellular carcinoma occurring in childhood. Report of three cases. Dig Dis Sci 1991;36:1143-1146
30. Pontisso P, Basso G, Perilongo G, et al. Does hepatitis B virus play a role in primary liver cancer in children of Western countries? Cancer Detect Prev 1991;15:363-368
31. Hsu HC, Wu MZ, Chang MH, et al. Childhood hepatocellular carcinoma develops exclusively in hepatitis B surface antigen carriers in three decades in Taiwan. Report of 51 cases strongly associated with rapid development of liver cirrhosis. J Hepatol 1987;5:260-267
32. Ni YH, Chang MH, Huang LM, et al. Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination. Ann Intern Med 2001;135:796-800
33. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:1-36
34. European association for the study of the liver. EASL Clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009;50:227-242
35. Jara P, Bortolotti F. Interferon-alpha treatment of chronic hepatitis B in childhood: a consensus advice based on experience in European children. J Pediatr Gastroenterol Nutr 1999;29:163-170
36. Lai CL, Lok AS, Lin HJ, et al. Placebo-controlled trial of recombinant alpha 2-interferon in Chinese HBsAg-carrier children. Lancet 1987;2:877-880
37. Lai CL, Lin HJ, Lau JN, et al. Effect of recombinant alpha 2 interferon with or without prednisone in Chinese HBsAg carrier children. Q J Med 1991;78:155-163
38. Lok AS, Lai CL, Wu PC, et al. Treatment of chronic hepatitis B with interferon: experience in Asian patients. Semin Liver Dis 1989;9:249-253
39. Bortolotti F, Jara P, Barbera C, et al. Long-term effect of alpha interferon in children with chronic hepatitis B. Gut 2000;46:715-718
40. Ruiz-Moreno M, Camps T, Jimenez J, et al. Factors predictive of response to interferon therapy in children with chronic hepatitis B. J Hepatol 1995;22:540-544
41. Ruiz Moreno M, Jimenez J, Porres JC, et al. A controlled trial of recombinant interferon-alpha in Caucasian children with chronic hepatitis B. Digestion 1990;45:26-33
42. Sokal EM, Wirth S, Goyens P, et al. Interferon alfa-2b therapy in children with chronic hepatitis B. Gut 1993;34:S87-90
43. Sokal EM, Conjeevaram HS, Roberts EA, et al. Interferon alfa therapy for chronic hepatitis B in children: a multinational randomized controlled trial. Gastroenterology 1998;114:988-995
44. Utili R, Sagnelli E, Galanti B, et al. Prolonged treatment of children with chronic hepatitis B with recombinant alpha 2a-interferon: a controlled, randomized study. Am J Gastroenterol 1991;86:327-330
45. Barbera C, Bortolotti F, Crivellaro C, et al. Recombinant interferon-alpha 2a hastens the rate of HBeAg clearance in children with chronic hepatitis B. Hepatology 1994;20:287-290
46. Vajro P, Tedesco M, Fontanella A, et al. Prolonged and high dose recombinant interferon alpha-2b alone or after prednisone priming accelerates termination of active viral replication in children with chronic hepatitis B infection. Pediatr Infect Dis J 1996;15:223-231
47. Sira JK, Sleight E, Boxall E, et al. Treatment of chronic hepatitis B carrier children in the UK [abstract 110]. Hepatology 1994;20:472
48. Giacchino R, Main J, Timitilli A, et al. Dual-centre, double-blind, randomised trial of lymphoblastoid interferon alpha with or without steroid pretreatment in children with chronic hepatitis B. Liver 1995;15:143-148
49. Gürakan F, Koçak N, Ozen H, Yüce A. Comparison of standard and high dosage recombinant interferon alpha 2b for treatment of children with chronic hepatitis B infection. Pediatr Infect Dis J 2000;19:52-56
50. Ruiz-Moreno M, Rua MJ, Molina J, et al. Prospective, randomized controlled trial of interferon-alpha in children with chronic hepatitis B. Hepatology 1991;13:1035-1039
51. Gregorio GV, Jara P, Hierro L, et al. Lymphoblastoid interferon alpha with or without steroid pretreatment in children with chronic hepatitis B: a multicentre controlled trial. Hepatology 1996;23:700-707
52. Torre D, Tambini R. Interferon-alpha therapy for chronic hepatitis B in children: a meta-analysis. Clin Infect Dis 1996;23:131-137
53. Verucchi G, Attard L, Mori F, et al. Interferon alpha is efficient in the treatment of children with chronic hepatitis B [abstract]. Hepatology 1994;20:301A
54. Iorio R, Pensati P, Botta S, et al. Side effects of alpha-interferon therapy and impact on health-related quality of life in children with chronic viral hepatitis. Pediatr Infect Dis J 1997;16:984-990
55. Lin ZQ, Fang F, Guo ZF, Chen Q. Effect of interferonalpha treatment in children with hepatitis B e antigenpositive chronic hepatitis B virus infection: a metaanalysis of follow-up for six months to two years. Zhonghua Er Ke Za Zhi 2007;45:592-598
56. Kobak GE, MacKenzie T, Sokol RJ, Narkewicz MR. Interferon treatment for chronic hepatitis B: enhanced response in children 5 years old or younger. J Pediatr 2004;145:340-345
57. Liu CJ, Kao JH, Chen DS. Therapeutic implications of hepatitis B virus genotypes. Liver Int 2005;25:1097-1107
58. Zhao H, Kurbanov F, Wan MB, et al. Genotype B and younger patient age associated with better response to low-dose therapy: a trial with pegylated/ nonpegylated interferon-alpha-2b for hepatitis B e antigen-positive patients with chronic hepatitis B in China. Clin Infect Dis 2007;44:541-548
59. Vajro P, Migliaro F, FontanellaA, Orso G. Interferon: a meta-analysis of published studies in pediatric chronic hepatitis B. Acta Gastroenterol Belg 1998;61:219-223
60. Iorio R, Giannattasio A, Cirillo F, et al. Long-term outcome in children with chronic hepatitis B: a 24-year observation period. Clin Infect Dis 2007;45:943-949
61. Diem HVT, Bourgois A, Bontems P, et al. Chronic hepatitis B infection: long term comparison of children receiving interferon-alpha and untreated controls. J Pediatr Gastroenterol Nutr 2005;40:141-145
62. Ertem D, Acar Y, Kotiloglu Karaa E, Pehlivanoglu E. High-dose interferon results in high HBsAg seroclearance in children with chronic hepatitis B infection. Turk J Pediatr 2003;45:123-128
63. Ozen H, Kocak N, Yuce A, Gurakan F. Retreatment with higher dose interferon alpha in children with chronic hepatitis B infection. Pediatr Infect Dis J 1999;18:694-697
64. Mellerup MT, Krogsgaard K, Mathurin P, et al. Sequential combination of glucocorticosteroids and alfa interferon versus alfa interferon alone for HBeAg-positive chronic hepatitis B. Cochrane Database Syst Rev 2009;4:CD000345
65. Boxall EH, Sira J, Ballard AL, et al. Long-term follow-up of hepatitis B carrier children treated with interferon and prednisolone. J Med Virol 2006;78:888-895
66. Pawloska M, Halota W. Virological response during treatment of chronic hepatitis B with pegylated interferon alfa-2a in children [abstract M1922]. Gastroenterology 2008:A811
67. Michaud AP, Bauman NM, Burke DK, et al. Spastic diplegia and other motor disturbances in infants receiving interferon-alpha. Laryngoscope 2004;114:1231-1236
68. Dienstag JL, Schiff ER, Mitchell M, et al. Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy. Hepatology 1999;30:1082-1087
69. Hadziyannis SJ, Papatheodoridis GV, Dimou E, et al. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2000;32:847-851
70. Liaw YF, Chien RN, Yeh CT, et al. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999;30:567-572
71. Sokal EM, Roberts EA, Mieli-Vergani G, et al. A dose ranging study of the pharmacokinetics, safety, and preliminary efficacy of lamivudine in children and adolescents with chronic hepatitis B. Antimicrob Agents Chemother 2000;44:590-597
72. Jonas MM, Mizerski J, Badia IB, et al. Clinical trial of lamivudine in children with chronic hepatitis B. N Engl J Med 2002;346:1706-1713
73. Sokal EM, Kelly DA, Mizerski J, et al. Long-term lamivudine therapy for children with HBeAg-positive chronic hepatitis B. Hepatology 2006;43:225-232
74. Jonas MM, Little NR, Gardner SD; International Pediatric Lamivudine Investigator Group. Long-term lamivudine treatment of children with chronic hepatitis B: durability of therapeutic responses and safety. J Viral Hepat 2008;15:20-27
75. Liberek A, Szaflarska-Popławska A, Korzon M, et al. Lamivudine therapy for children with chronic hepatitis B. World J Gastroenterol 2006;12:2412-2416
76. Choe BH, Lee JH, Jang YC, et al. Long-term therapeutic efficacy of lamivudine compared with interferon-alpha in children with chronic hepatitis B: the younger the better. J Pediatr Gastroenterol Nutr 2007;44:92-98
77. Koh H, Baek SY, Chung KS. Lamivudine therapy for korean children with chronic hepatitis B. Yonsei Med J 2007;48:927-933
78. Ozgenç F, Arikan C, Sertoz RY, et al. Effect of long-term lamivudine in chronic hepatitis B virus-infected children. Antivir Ther 2004;9:729-732
79. Hartman C, Berkowitz D, Eshach-Adiv O, et al. Long-term lamivudine therapy for chronic hepatitis B infection in children unresponsive to interferon. J Pediatr Gastroenterol Nutr 2006;43:494-498
80. Selimoglu MA, Aydogdu S, Unal F, et al. Alpha interferon and lamivudine combination therapy for chronic hepatitis B in children. Pediatr Int 2002;44:404-408
81. Dikici B, Bosnak M, Kara IH, et al. Lamivudine and interferon-alpha combination treatment of childhood patients with chronic hepatitis B infection. Pediatr Infect Dis J 2001;20:988-992
82. Dikici B, Bosnak M, Bosnak V, et al. Comparison of treatments of chronic hepatitis B in children with lamivudine and alpha-interferon combination and alpha-interferon alone. Pediatr Int 2002;44:517-521
83. Elkabes B, Suoglu OD, Sokucu S, Saner G. Lamivudine and alpha interferon combination treatment versus alpha interferon treatment in children with chronic hepatitis B infection. J Hepatol 2001:161
84. Sokucu S, Gokçe S, Suoglu OD, et al. Comparison of interferon monotherapy with interferon-lamivudine combination treatment in children with chronic hepatitis B. Indian J Gastroenterol 2006;25:136-139
85. Kocak N, Ozen H, Saltik IN, et al. Comparison of lamivudine (LMV) with LMV + interferon (IFN)-alpha treatments in children with chronic hepatitis B (CHB) who were nonresponders to previous IFN-alpha treatment. J Ped Gastroenterol Nutr 2000;31:1063A
86. Kutlu T, cullu F, Erkan T, Tümay GT. Lamivudine and alpha interferon combination therapy for chronic hepatitis B infection in children: a preliminary trial. J Pediatr Gastroenterol Nutr 2000;31:443
87. Akman SA, Okcu SC, Halicioglu O, et al. Therapeutic efficacy of sequential and simultaneous treatments with interferon-alpha and lamivudine in children with chronic hepatitis B. Pediatr Int 2007;49:848-852
88. Hartman C, Berkowitz D, Shouval D, et al. Lamivudine treatment for chronic hepatitis B infection in children unresponsive to interferon. Pediatr Infect Dis J 2003;22:224-229
89. Saltik Temizel IN, Kocak N, Demir H, et al. Two years results of lamivudine (LMV) alone and LMV plus interferon (IFN) treatment in children with chronic hepatitis B (CHB) who were non-responders to IFN. J Hepatol 2003;38:168-169
90. Arif B, Selim I, Ferhan K, Ismail G. Efficacy of interferon alpha-2b and lamivudine therapy for chronic hepatitis B in children. Chin Med J (Engl) 2003;116:593-596
91. D Antiga L, Aw M, Atkins M, et al. Combined lamivudine/interferon-alpha treatment in 'immunotolerant' children perinatally infected with hepatitis B: a pilot study. J Pediatr 2006;148:228-233
92. Perrillo R, Schiff E, Yoshida E, et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000;32:129-134
93. Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003;348:808-816
94. Jonas MM, Kelly D, Pollack H, et al. Safety, efficacy, and pharmacokinetics of adefovir dipivoxil in children and adolescents (age 2 to< 18 years) with chronic hepatitis B. Hepatology, 2008, 47:1863-1871
95. Safety and efficacy of adefovir dipivoxil in children and adolescents with chronic hepatitis B. NCT00095121. Available from http://www.clinicaltrial. gov/ct2/ show/NCT00095121 [Last accessed 1 Dec 2009]
96. Kuo A, Dienstag JL, Chung RT. Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B. Clin Gastroenterol Hepatol 2004;2:266-272
97. van Bommel F, Wunsche T, Mauss S, et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 2004;40:1421-1425
98. Marcellini P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008;359:2442-2455
99. Evaluation of tenofovir disoproxil fumarate in adolescents with chronic hepatitis B infection. NCT00734162. Available from http://www.clinicaltrial.gov/ ct2/show/NCT000734162 [Last accessed 1 Dec 2009]
100. Lai CL, Gane E, Chao-Wei H, et al. Two-year results from the Globe Trial in patients with hepatitis B: greater clinical and antiviral efficacy for telbivudine (LDT) vs. lamivudine. Hepatology 2006;44:222A
101. Di Bisceglie AM, Lai CL, Gane E, et al. Telbivudine Globe Trial: maximal early HBV suppression is predictive of optimal two-year efficacy in nucleoside-treated hepatitis B patients. Hepatology 2006;44:230-1A
102. Pharmacokinetics and safety of single-dose telbivudine in children and adolescents with chronic hepatitis B. NCT00907894. Available from http://clinicaltrials.gov/ct2/show/NCT00907894 [Last accessed 1 Dec 2009]
103. Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354:1001-1010
104. Sherman M, Yurdaydin C, Sollano J, et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006;130:2039-2049
105. Kohrt HE, Ouyang DL, Keeffe EB. Antiviral prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Clin Liver Dis 2007;11:965-991
106. Cheng AL, Hsiung CA, Su IJ, et al. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology 2003;37:1320-1328
107. Yeo W, Chan PK, Zhong S, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000;62:299-307
108. Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006;43:209-220
109. Faraci M, Cappelli B, Lanino E, et al. Hepatitis B reactivation in allogeneic hemopoietic stem cell transplantation setting: a pediatric experience. Pediatr Transplant 2009;13:923-926
110. Katz LH, Fraser A, Gafter-Gvili A, et al. Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: systematic review and meta-analysis. J Viral Hepat 2008;15:89-102
111. Andreone P, Fiorino S, Cursaro C, et al. Vitamin E as treatment for chronic hepatitis B: results of a randomized controlled pilot trial. Antiviral Res 2001;49:75-81
112. Gerner P, Posselt HG, Krahl A, et al. Vitamin E treatment for children with chronic hepatitis B: a randomized placebo controlled trial. World J Gastroenterol 2008;14:7208-7213
113. Fattovich G, Cadrobbi P, Crivellaro C, et al. Virological changes in chronic hepatitis type B treated with levamisole. Digestion 1982;25:131-137
114. Krastev Z, Jelev D, Antonov K, et al. Chronic HBV infection. Immunomodulation with levamisole in viremic HBeAg positive or anti-HBe positive patients-a pilot study. Hepatogastroenterology 1999;46:3184-3188
115. Ruiz-Moreno M, Garćia R, Rua MJ, et al. Levamisole and interferon in children with chronic hepatitis B. Hepatology 1993;18:264-269
116. Karaoglan M, Demirci F, Coskun Y, et al. Immunomodulation therapy in children with chronic hepatitis B. J Natl Med Assoc 2006;98:143-147
117. Senturk H, Tabak F, Ozaras R, et al. Efficacy of pre-S-containing HBV vaccine combined with lamivudine in the treatment of chronic HBV infection. Dig Dis Sci 2009;54:2026-2030